INCR INC Research Holdings Inc

Syneos Health Appoints William E. Klitgaard Independent Director

Syneos Health Appoints William E. Klitgaard Independent Director

MORRISVILLE, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of William E. Klitgaard to its Board of Directors. Mr. Klitgaard was previously a member of the Syneos Board from 2017 until May 2022, having resigned due to a personal matter. The Company also announced today that Todd M. Abbrecht is stepping down from its Board of Directors.

“We are excited to welcome Bill back to the Syneos Health Board,” said John Dineen, Chair of the Syneos Health Board of Directors. “Bill’s deep financial expertise combined with his knowledge of our company are a welcome addition to an already strong Board, enhancing its composition. This appointment will support continued successful oversight of our strategy as we speed our customers’ delivery of important therapies to patients.”

Mr. Dineen added, “Syneos Health has been well served by Todd’s contributions, and we thank him for his years of service to the Company.”

Mr. Klitgaard will serve as a Class II director and as a member of the Company’s Audit Committee. With these changes, the Syneos Health Board remains comprised of 10 directors, 9 of whom are independent.

William E. Klitgaard

Mr. Klitgaard currently serves on the board of directors of XIFIN, Inc., a health information technology company and Avista Public Acquisition Corp. II, a special purpose acquisition company, where he serves as the Chair of the Audit Committee.

Mr. Klitgaard was an Operating Executive at Avista Capital Partners, a private equity firm focused on healthcare from 2020 to 2021. He previously served as the President of Enlighten Health, a division of LabCorp from 2015 to 2016. He also held various roles over his 19-year career at Covance, including three years as Corporate Senior Vice President and Chief Information Officer, and nearly twelve years as Corporate Senior Vice President and Chief Financial Officer. He received his Bachelor of Arts in Economics from the University of California at Berkeley, and his Masters of Science from the Sloan Management School at the Massachusetts Institute of Technology.

About Syneos Health

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, strategically integrating clinical development, medical affairs and commercial capabilities to address modern market realities.

We bring together more than 29,000 minds, across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.

To learn more about how we are Shortening the distance from lab to life®, visit or .

Investor Relations Contact:Press/Media Contact:
Ronnie SpeightGary Gatyas
Senior Vice President, Investor RelationsExecutive Director, External Communications


EN
14/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on INC Research Holdings Inc

 PRESS RELEASE

Syneos Health Closes Transaction with Private Investment Firms

Syneos Health Closes Transaction with Private Investment Firms Transaction Will Drive Ongoing Transformation and Accelerate Delivery of Tech-Enabled, Fit-for-Purpose Solutions to Biopharma Customers MORRISVILLE, N.C., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today announced the completion of its acquisition by a consortium of private investment firm affiliates composed of Elliott Investment Management L.P., Patient Square Capital and Veritas Capital. As a result of the...

 PRESS RELEASE

Syneos Health Names Terttu Haring President, Clinical Sites & Patients

Syneos Health Names Terttu Haring President, Clinical Sites & Patients Industry Veteran to Play Critical Role in Leading Global Clinical Operations, Cultivating Site Relationships, Empowering Patients and Shaping Innovative Clinical Trial Solutions MORRISVILLE, N.C., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, has announced the appointment of Terttu Haring, MD, as President, Clinical Sites & Patients. With nearly 30 years of experience, Dr. Haring will lead the global clinical operations organizat...

 PRESS RELEASE

Syneos Health and Oracle to Expand Relationship to Accelerate Patient ...

Syneos Health and Oracle to Expand Relationship to Accelerate Patient Recruitment & Advance Health Equity MORRISVILLE, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic collaboration that will expand its relationship with Oracle. Using the Oracle Cerner Learning Health Network (LHN) and elements of Oracle’s suite of study startup solutions, the companies seek to help reduce the time it takes to recruit patients for clinical studies and increase the diversity of patient pop...

 PRESS RELEASE

Syneos Health, Inc. and Star Parent, Inc. Announce Proposed $1.70 Bill...

Syneos Health, Inc. and Star Parent, Inc. Announce Proposed $1.70 Billion Offering of Senior Secured Notes MORRISVILLE, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Star Parent, Inc. (the “Issuer” or the “Company”) and Syneos Health, Inc. (“Syneos Health”), announced today that, subject to market conditions and other factors, the Issuer intends to offer $1,700,000,000 aggregate principal amount of Senior Secured Notes due 2030 (the “Notes”). The Issuer intends to use the proceeds from the offering together with other financing sources to fund the previously announced acquisition of Syneos Hea...

 PRESS RELEASE

Syneos Health Stockholders Approve Agreement with Private Investment C...

Syneos Health Stockholders Approve Agreement with Private Investment Consortium MORRISVILLE, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today announced that the Company’s stockholders approved an agreement to take the Company private through an acquisition by a consortium of private investment firm affiliates comprised of Elliott Investment Management L.P., Patient Square Capital, and Veritas Capital at a special meeting of stockholders held earlier toda...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch